Original Article from The New England Journal of Medicine — Rapid Dissemination of β-Lactamase–Producing, Aminoglycoside-Resistant Enterococcus faecalis among Patients and Staff on an Infant–Toddler Surgical Ward

Enterococcus faecalis

Toddler

10.1056/nejm199012273232606

Cite

Citations (215)

Linezolid: The First Oxazolidinone Antimicrobial

Annals of Internal Medicine (2003)

Robert C. Moellering

Letters18 November 2003Linezolid: The First Oxazolidinone AntimicrobialRobert C. Moellering Jr., MDRobert C. Moellering Jr., MDFrom Harvard Medical School; Beth Israel Deaconess Medical Center.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-139-10-200311180-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Johnson is correct in his comments about TMP-SMX as a potential therapeutic agent for MRSA infections. As he points out, however, because the drug is no longer subject to patent protection, it is highly unlikely that a large-scale comparative study of this agent will be undertaken for MRSA infections. In this context, unlike the recently described vancomycin-resistant MRSA (which thus far is very rare), the strains that are resistant to TMP-SMX do occur and, of course, would not be expected to respond to that agent.Dr. Lindley is also correct: The oral formulation of linezolid is very ... Author, Article, and Disclosure InformationAuthors: Robert C. MoelleringJr., MDAffiliations: From Harvard Medical School; Beth Israel Deaconess Medical Center. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoLinezolid: The First Oxazolidinone Antimicrobial Robert C. Moellering Jr. Linezolid: The First Oxazolidinone Antimicrobial James R. Johnson Linezolid: The First Oxazolidinone Antimicrobial D. A. Lindley Linezolid: The First Oxazolidinone Antimicrobial David L. Paterson , A. William Pasculle , and Kenneth McCurry Metrics Cited byScreening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discoveryCurrent advances in the clinical development of anti-tubercular agentsSynthesis of Chiral N-Nitro-oxazolidin-2-ones and O-(β-Nitraminoalkyl) Carbamates in Liquefied 1,1,1,2-Tetrafluoroethane MediumMicrobial Natural Products in Drug Discovery 18 November 2003Volume 139, Issue 10Page: 864KeywordsAntibioticsAntimicrobialsDrug therapyDrugsHospitalizationsMethicillin-resistant staphylococcus aureusOutpatientsVancomycin ePublished: 18 November 2003 Issue Published: 18 November 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...

Linezolid

10.7326/0003-4819-139-10-200311180-00018

Cite

Citations (10)

Endocarditis due to group D streptococci

The American Journal of Medicine (1974)

Robert C. Moellering Barbara K. Watson Lawrence J. Kunz

Streptococcus bovis

Viridans streptococci

Group A

Antibiotic Therapy

10.1016/0002-9343(74)90448-3

Cite

Citations (156)

Lack of Bactericidal Antagonism or SynergismIn Vitrobetween Oxacillin and Vancomycin against Methicillin-Susceptible Strains ofStaphylococcus aureus

Antimicrobial Agents and Chemotherapy (2009)

Christian Joukhadar Satish K. Pillai Christine Wennersten Robert C. Moellering George M. Eliopoulos

ABSTRACT With the current high prevalence of infection caused by methicillin-resistant Staphylococcus aureus (MRSA) strains but in light of the general belief that β-lactam antibiotics are more effective than vancomycin against infections caused by methicillin-susceptible S. aureus (MSSA) isolates, clinicians may utilize antistaphylococcal penicillins in combination with vancomycin for the empirical treatment of S. aureus infections. Vancomycin is considered to kill MSSA more slowly than oxacillin. Thus, we sought to evaluate the interaction of the combination of oxacillin and vancomycin on bacterial killing in vitro . Ten clinical isolates of MSSA isolated in the year 2000 were investigated. The killing observed at 24 h by vancomycin at 20 μg/ml, oxacillin at 16 μg/ml, or the combination did not differ (approximately 2.5 to 3.5 log 10 CFU/ml). In a separate experiment, we assessed bacterial killing in a dynamic model simulating the free plasma concentration profiles expected following the administration of a combination of vancomycin at 1 g every 12 h and oxacillin at 1 g every 6 h. The time-kill profiles of these regimens against S. aureus ATCC 29213 were comparable to those observed in the fixed-concentration experiments. Using these methods, we found no evidence that vancomycin antagonized the bactericidal effect of oxacillin or that there was any benefit from use of the combination.

Meticillin

10.1128/aac.00348-09

Cite

Citations (18)

Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds

Journal of Antimicrobial Chemotherapy (1988)

Jennifer S. Daly George M. Eliopoulos E Reiszner Robert C. Moellering

Journal Article Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds Get access Jennifer S. Daly, Jennifer S. Daly aDepartment of Medicine, New England Deaconess HospitalbHarvard Medical SchoolBoston, MA 02215, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar George M. Eliopoulos, George M. Eliopoulos aDepartment of Medicine, New England Deaconess HospitalbHarvard Medical SchoolBoston, MA 02215, USA Correspondence address: Dr George M. Eliopoulos, Department of Medicine, New England Deaconess Hospital, 110 Francis Street, Boston, MA 02215, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Edina Reiszner, Edina Reiszner aDepartment of Medicine, New England Deaconess Hospital Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert C. Moellering, Jr Robert C. Moellering, Jr aDepartment of Medicine, New England Deaconess HospitalbHarvard Medical SchoolBoston, MA 02215, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Journal of Antimicrobial Chemotherapy, Volume 21, Issue 6, June 1988, Pages 721–730, https://doi.org/10.1093/jac/21.6.721 Published: 01 June 1988 Article history Received: 30 October 1987 Accepted: 02 February 1988 Published: 01 June 1988

George (robot)

New england

10.1093/jac/21.6.721

Cite

Citations (64)

Prevalence of the fsr Locus in Enterococcus faecalis Infections

Journal of Clinical Microbiology (2002)

Satish K. Pillai George Sakoulas Howard S. Gold Christine Wennersten George M. Eliopoulos

The fsr locus of Enterococcus faecalis confers virulence in animal models. A retrospective analysis of fsr prevalence in diverse E. faecalis clinical isolates demonstrated fsr in all endocarditis isolates versus 53% of stool isolates (P = 0.005). This supports a role for fsr-mediated virulence in the pathogenesis of enterococcal infections in humans.

Enterococcus faecalis

10.1128/jcm.40.7.2651-2652.2002

Cite

Citations (44)

Penicillin-Tobramycin Synergism Against Enterococci: a Comparison with Penicillin and Gentamicin

Antimicrobial Agents and Chemotherapy (1973)

Robert C. Moellering Christine Wennersten Allan J. Weinstein

Combinations of penicillin plus tobramycin have been compared with penicillin plus gentamicin against 27 strains of enterococci isolated from blood cultures. Penicillin plus gentamicin was synergistic against all strains. The combination of penicillin plus tobramycin was equally effective against strains of Streptococcus facalis, but was ineffective against all four strains of S. faecium tested.

10.1128/aac.3.4.526

Cite

Citations (59)